London, UK, December 20, 2017 — Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing. Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare … Continue reading Orchard Therapeutics Announces $110M Series B Financing